Sonidegib Shortage: What Providers and Prescribers Need to Know in 2026

For oncologists, dermatologists, and dermatologic oncologists managing patients with locally advanced basal cell carcinoma (laBCC), Sonidegib (Odomzo) remains one of only a few FDA-approved systemic options. However, the reality of prescribing this medication in 2026 involves navigating a highly restricted distribution system, rigorous insurance requirements, and significant safety monitoring obligations.

This guide summarizes what prescribers need to know about Sonidegib access and patient management in 2026.

Current Availability Status

Sonidegib is not currently listed on the FDA drug shortage database. However, it remains a restricted-distribution specialty drug available only through Sun Pharma's OdomzoCARE specialty pharmacy network. No generic equivalent is FDA-approved, and none is expected imminently given remaining patent protections.

The key access challenges providers encounter in 2026 include:

Mandatory prior authorization across virtually all commercial and government payer plans

Specialty pharmacy routing requirements — prescriptions cannot be sent to retail pharmacies

Tier 5 formulary placement on Medicare Part D plans, leading to high patient cost-sharing without assistance programs

Step therapy requirements at some payers (prior trial of surgery/radiation required, which is already part of the FDA indication)

FDA Indication: Who Qualifies for Sonidegib?

Sonidegib is FDA-indicated for adult patients with locally advanced BCC (laBCC) who fall into one of two categories:

laBCC that has recurred following surgery or radiation therapy

laBCC in patients who are not candidates for curative surgery or radiation therapy

Efficacy data come from the Phase II BOLT trial (NCT01327053), in which the objective response rate at a median follow-up of 38.2 months was 56.1% for laBCC patients receiving sonidegib 200 mg daily. The approved dose is 200 mg orally once daily on an empty stomach.

Critical Safety Monitoring Requirements

Sonidegib carries a boxed warning for embryo-fetal toxicity—the highest severity warning the FDA issues. Beyond that, musculoskeletal adverse events (particularly elevated creatine kinase and rhabdomyolysis) require active monitoring:

Baseline labs: Obtain serum CK levels and renal function tests prior to initiating Sonidegib in all patients.

Ongoing monitoring: Repeat CK and renal function testing as clinically indicated, especially with muscle-related symptoms.

Dose interruption for CK elevation: Interrupt for first occurrence of CK 2.5-10× ULN; permanently discontinue for CK >10× ULN or recurrent CK >5× ULN, or with worsening renal function.

Reproductive risk counseling: Females of reproductive potential require a pregnancy test before initiation, effective contraception during treatment and for 20 months post-treatment, and must not donate blood for 20 months. Males must use condoms (even post-vasectomy) during treatment and for 8 months, and must not donate semen for 8 months.

Key Drug Interactions Prescribers Must Know

Sonidegib is a CYP3A substrate with significant drug interaction potential:

Avoid strong CYP3A inhibitors (azole antifungals, ritonavir, amiodarone, adagrasib) — coadministration increases sonidegib exposure approximately 2.2-fold, heightening musculoskeletal toxicity risk.

Avoid strong CYP3A inducers (carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort) — these reduce sonidegib plasma concentrations and may compromise efficacy.

Monitor with statins, chloroquine, hydroxychloroquine — concurrent use increases the risk of muscle-related adverse events including rhabdomyolysis.

38,004+ patients found their medications in stock

38K+

Find Sonidegib In Stock Today →

Prior Authorization: What Payers Typically Require

Based on standard payer criteria (e.g., BCBS, commercial plans), prior authorization for Sonidegib typically requires:

Confirmed diagnosis of locally advanced BCC (pathology/biopsy report)

Documentation that curative surgery or radiation is not feasible, OR documentation of disease recurrence after surgery or radiation

Prescriber must be a specialist (oncologist, dermatologist, or consulting with one)

Baseline lab results (CK, renal function) documented

Absence of contraindications (pregnancy, severe hepatic impairment, prohibited drug interactions)

When to Consider Alternatives for Your Patient

If your laBCC patient cannot access or tolerate Sonidegib, clinically recognized alternatives include:

Vismodegib (Erivedge): First-in-class SMO inhibitor with similar efficacy; 150 mg once daily; distributed through Genentech's specialty network. Lacks the rhabdomyolysis language of Sonidegib's label.

Cemiplimab (Libtayo): FDA-approved for laBCC in patients who have progressed on or are intolerant to hedgehog pathway inhibitors. Given as IV infusion q3w.

Skip the calls, skip the stress.

Find Sonidegib In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How medfinder Supports Providers

When your patients are struggling to fill their Sonidegib prescription, medfinder offers a service that calls pharmacies on behalf of patients to identify which ones can fill specific prescriptions—saving time and reducing patient frustration. You can refer your patients to medfinder or read our provider guide to helping patients find Sonidegib for practical strategies.

Key Takeaways for Prescribers

Sonidegib is not in an FDA-declared shortage as of 2026, but access challenges are real and structural

All prescriptions must be routed to the OdomzoCARE specialty pharmacy network

Prior authorization is virtually universal — submit documentation proactively

Baseline CK and renal function required before initiation; monitor throughout treatment

Counsel all patients of reproductive age on embryo-fetal toxicity and contraception requirements

For access-related delays, Vismodegib (Erivedge) is the most direct therapeutic alternative